JP2014528485A - ３，３−二置換１９−ノルプレグナン化合物およびその使用 - Google Patents
３，３−二置換１９−ノルプレグナン化合物およびその使用 Download PDFInfo
- Publication number
- JP2014528485A JP2014528485A JP2014535962A JP2014535962A JP2014528485A JP 2014528485 A JP2014528485 A JP 2014528485A JP 2014535962 A JP2014535962 A JP 2014535962A JP 2014535962 A JP2014535962 A JP 2014535962A JP 2014528485 A JP2014528485 A JP 2014528485A
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- certain embodiments
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 C[C@]1(C(CC2)C(CC(*)(*)[C@@](C3*)[C@@]4CC(*)[C@@]3(*)O*)C4C(C)(*)C1)[C@]2C(C*)=O Chemical compound C[C@]1(C(CC2)C(CC(*)(*)[C@@](C3*)[C@@]4CC(*)[C@@]3(*)O*)C4C(C)(*)C1)[C@]2C(C*)=O 0.000 description 19
- NQRYJNQNLNOLGT-UHFFFAOYSA-N C1CCNCC1 Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- AKNYNMDEUAVRQF-RVYMZYKISA-N CC(CC1)([C@@H](CC2)C(CC3)[C@H]1C(C)(CC1)C3C[C@]1(C#CC1CC1)O)[C@H]2C(C[n]1nncn1)=O Chemical compound CC(CC1)([C@@H](CC2)C(CC3)[C@H]1C(C)(CC1)C3C[C@]1(C#CC1CC1)O)[C@H]2C(C[n]1nncn1)=O AKNYNMDEUAVRQF-RVYMZYKISA-N 0.000 description 1
- UKWBYOFCXQRFJD-ISYAJLAZSA-N CC(CC1)([C@@H](CC2)C3[C@H]1[C@@H](CC[C@@](C1)(C#CCl)O)C1=CC3)[C@H]2C(C[n]1cncc1)=O Chemical compound CC(CC1)([C@@H](CC2)C3[C@H]1[C@@H](CC[C@@](C1)(C#CCl)O)C1=CC3)[C@H]2C(C[n]1cncc1)=O UKWBYOFCXQRFJD-ISYAJLAZSA-N 0.000 description 1
- QMJXHGIVOYMKCZ-FDFSZNRNSA-N CC(CC1)([C@@H](CC2)C3[C@H]1[C@@H](CC[C@](C)(C1)O)C1=CC3)[C@H]2C(C[n]1cncc1)=O Chemical compound CC(CC1)([C@@H](CC2)C3[C@H]1[C@@H](CC[C@](C)(C1)O)C1=CC3)[C@H]2C(C[n]1cncc1)=O QMJXHGIVOYMKCZ-FDFSZNRNSA-N 0.000 description 1
- HBTAMOHBEOMJBT-HHNOUVQWSA-N CC([C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@H](CC2)[C@@H]1CC2(OC)OC)O Chemical compound CC([C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@H](CC2)[C@@H]1CC2(OC)OC)O HBTAMOHBEOMJBT-HHNOUVQWSA-N 0.000 description 1
- XHIFSRUGOAREJS-UXFDRQSVSA-N CC[C@@H](CC1)[C@@](C)(CC2)[C@@H]1C(CC1)[C@H]2[C@@H](CC2)[C@@H]1CC21OC1 Chemical compound CC[C@@H](CC1)[C@@](C)(CC2)[C@@H]1C(CC1)[C@H]2[C@@H](CC2)[C@@H]1CC21OC1 XHIFSRUGOAREJS-UXFDRQSVSA-N 0.000 description 1
- PHNWTSAWNZCUSU-TXOKOKHKSA-N CC[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@H](CC2)[C@@H]1CC2=O Chemical compound CC[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@H](CC2)[C@@H]1CC2=O PHNWTSAWNZCUSU-TXOKOKHKSA-N 0.000 description 1
- NHGUZESDTZOMNT-RGDOEEFWSA-N C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1C(CC1)C3C[C@]1(COC)O)[C@H]2C(C[n]1nncn1)=O Chemical compound C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1C(CC1)C3C[C@]1(COC)O)[C@H]2C(C[n]1nncn1)=O NHGUZESDTZOMNT-RGDOEEFWSA-N 0.000 description 1
- GFTUILSHVDSPMF-WCYVBRDLSA-N C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1C(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(CBr)=O Chemical compound C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1C(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(CBr)=O GFTUILSHVDSPMF-WCYVBRDLSA-N 0.000 description 1
- GDVNEVRDAKDCGD-ZABLSFTFSA-N C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1C(CC1)[C@@H]3C[C@]1(COC)O)[C@H]2C(CBr)=O Chemical compound C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1C(CC1)[C@@H]3C[C@]1(COC)O)[C@H]2C(CBr)=O GDVNEVRDAKDCGD-ZABLSFTFSA-N 0.000 description 1
- KCAJIXCJGVSNGQ-BNOKSRODSA-N C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1[C@@H](CC1)C3C[C@@]1(O)F)[C@H]2C(C[n]1nncc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1[C@@H](CC1)C3C[C@@]1(O)F)[C@H]2C(C[n]1nncc1)=O KCAJIXCJGVSNGQ-BNOKSRODSA-N 0.000 description 1
- JIWJWZQRCFJBIU-AGGNEXECSA-N C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(COC)O)[C@H]2C(C)=O Chemical compound C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(COC)O)[C@H]2C(C)=O JIWJWZQRCFJBIU-AGGNEXECSA-N 0.000 description 1
- BJGRFMVIXJYDHI-OMJMBDCTSA-N C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(COC)O)[C@H]2C(CO)=O Chemical compound C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(COC)O)[C@H]2C(CO)=O BJGRFMVIXJYDHI-OMJMBDCTSA-N 0.000 description 1
- IOOAGXADVABKCP-WNPFIWHSSA-N C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(CF)O)[C@H]2C(C[n]1nncn1)=O Chemical compound C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(CF)O)[C@H]2C(C[n]1nncn1)=O IOOAGXADVABKCP-WNPFIWHSSA-N 0.000 description 1
- ZXKJEOVCJDVXIF-QEKYLOJESA-N C[C@](CC1)([C@@H](CC2)C3[C@H]1C(CC[C@@](C1)(C(F)F)O)C1=CC3)[C@H]2C(C[n]1cncc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)C3[C@H]1C(CC[C@@](C1)(C(F)F)O)C1=CC3)[C@H]2C(C[n]1cncc1)=O ZXKJEOVCJDVXIF-QEKYLOJESA-N 0.000 description 1
- WWNFXUGTTGDMNF-PQYWPEKISA-N C[C@](CC1)([C@@H](CC2)C3[C@H]1C(CC[C@](CF)(C1)O)C1=CC3)[C@H]2C(C[n]1nccn1)=O Chemical compound C[C@](CC1)([C@@H](CC2)C3[C@H]1C(CC[C@](CF)(C1)O)C1=CC3)[C@H]2C(C[n]1nccn1)=O WWNFXUGTTGDMNF-PQYWPEKISA-N 0.000 description 1
- GSSGXDPDFATYKP-HCCUAEHMSA-N C[C@](CC1)([C@@H](CC2)C3[C@H]1[C@@H](CC[C@](C)(C1)O)C1=CC3)[C@H]2C(C[n]1nccn1)=O Chemical compound C[C@](CC1)([C@@H](CC2)C3[C@H]1[C@@H](CC[C@](C)(C1)O)C1=CC3)[C@H]2C(C[n]1nccn1)=O GSSGXDPDFATYKP-HCCUAEHMSA-N 0.000 description 1
- VUIGKASVJDGUGL-BOCYWOPZSA-N C[C@](CC1)([C@@H](CC2)C3[C@H]1[C@@H](CC[C@](COC)(C1)O)C1=CC3)[C@H]2C(C[n]1nccn1)=O Chemical compound C[C@](CC1)([C@@H](CC2)C3[C@H]1[C@@H](CC[C@](COC)(C1)O)C1=CC3)[C@H]2C(C[n]1nccn1)=O VUIGKASVJDGUGL-BOCYWOPZSA-N 0.000 description 1
- GEJDELDOOCQBCA-KOEILBIASA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1C(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(CO)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1C(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(CO)=O GEJDELDOOCQBCA-KOEILBIASA-N 0.000 description 1
- TUUANTKFDPCXBK-YMZTYRIISA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3CC11OC1)[C@H]2C(C)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3CC11OC1)[C@H]2C(C)=O TUUANTKFDPCXBK-YMZTYRIISA-N 0.000 description 1
- XAVWFOOPIKBVTO-QKAVBZAFSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3CC1=O)C2=C Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3CC1=O)C2=C XAVWFOOPIKBVTO-QKAVBZAFSA-N 0.000 description 1
- DXVAYRMRHRBFBX-VGLNAJPOSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C#CCl)O)[C@H]2C(C[n]1nncn1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C#CCl)O)[C@H]2C(C[n]1nncn1)=O DXVAYRMRHRBFBX-VGLNAJPOSA-N 0.000 description 1
- WYJUTWNVUFMJTQ-FGEHLQNISA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C(F)F)O)[C@H]2C(C[n]1nncn1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C(F)F)O)[C@H]2C(C[n]1nncn1)=O WYJUTWNVUFMJTQ-FGEHLQNISA-N 0.000 description 1
- ZRPJWPAGXBTUNI-GVKWWOCJSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C)O)[C@H]2C(CN1N=CN=C(C)C1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C)O)[C@H]2C(CN1N=CN=C(C)C1)=O ZRPJWPAGXBTUNI-GVKWWOCJSA-N 0.000 description 1
- BKWFZSTUDUFACP-DLRZCKRASA-N C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1C(CC[C@](CF)(C1)O)C1=CC3)[C@H]2C(C[n]1cncc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1C(CC[C@](CF)(C1)O)C1=CC3)[C@H]2C(C[n]1cncc1)=O BKWFZSTUDUFACP-DLRZCKRASA-N 0.000 description 1
- NGSVUQGFZUSWCC-UIUWFLJTSA-N C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@](C)(C1)O)C1=CC3)[C@H]2C(CN1CCCC1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@](C)(C1)O)C1=CC3)[C@H]2C(CN1CCCC1)=O NGSVUQGFZUSWCC-UIUWFLJTSA-N 0.000 description 1
- QMJXHGIVOYMKCZ-UXYSYXNWSA-N C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@](C)(C1)O)C1=CC3)[C@H]2C(C[n]1cncc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@](C)(C1)O)C1=CC3)[C@H]2C(C[n]1cncc1)=O QMJXHGIVOYMKCZ-UXYSYXNWSA-N 0.000 description 1
- NELGOKVQFDGBPO-FZHBBNGRSA-N C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@](CCC1CC1)(C1)O)C1=CC3)[C@H]2C(C[n]1cncc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@](CCC1CC1)(C1)O)C1=CC3)[C@H]2C(C[n]1cncc1)=O NELGOKVQFDGBPO-FZHBBNGRSA-N 0.000 description 1
- BKWFZSTUDUFACP-VHHRSFCGSA-N C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@](CF)(C1)O)C1=CC3)[C@H]2C(C[n]1cncc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@](CF)(C1)O)C1=CC3)[C@H]2C(C[n]1cncc1)=O BKWFZSTUDUFACP-VHHRSFCGSA-N 0.000 description 1
- ULUAZAZIOYFRTO-HMSJMEEOSA-N C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@](COC)(C1)O)C1=CC3)[C@H]2C(C[n]1cncc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@](COC)(C1)O)C1=CC3)[C@H]2C(C[n]1cncc1)=O ULUAZAZIOYFRTO-HMSJMEEOSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
- C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Fats And Perfumes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161547291P | 2011-10-14 | 2011-10-14 | |
| US61/547,291 | 2011-10-14 | ||
| US201261698204P | 2012-09-07 | 2012-09-07 | |
| US61/698,204 | 2012-09-07 | ||
| PCT/US2012/060136 WO2013056181A1 (en) | 2011-10-14 | 2012-10-12 | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017235371A Division JP6745783B2 (ja) | 2011-10-14 | 2017-12-07 | ３，３−二置換１９−ノルプレグナン化合物およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014528485A true JP2014528485A (ja) | 2014-10-27 |
| JP2014528485A5 JP2014528485A5 (enExample) | 2015-11-12 |
Family
ID=47143295
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014535962A Withdrawn JP2014528485A (ja) | 2011-10-14 | 2012-10-12 | ３，３−二置換１９−ノルプレグナン化合物およびその使用 |
| JP2017235371A Active JP6745783B2 (ja) | 2011-10-14 | 2017-12-07 | ３，３−二置換１９−ノルプレグナン化合物およびその使用 |
| JP2020132282A Active JP7096864B2 (ja) | 2011-10-14 | 2020-08-04 | ３，３－二置換１９－ノルプレグナン化合物およびその使用 |
| JP2022101881A Active JP7617057B2 (ja) | 2011-10-14 | 2022-06-24 | ３，３－二置換１９－ノルプレグナン化合物およびその使用 |
| JP2025001804A Pending JP2025061026A (ja) | 2011-10-14 | 2025-01-06 | ３，３－二置換１９－ノルプレグナン化合物およびその使用 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017235371A Active JP6745783B2 (ja) | 2011-10-14 | 2017-12-07 | ３，３−二置換１９−ノルプレグナン化合物およびその使用 |
| JP2020132282A Active JP7096864B2 (ja) | 2011-10-14 | 2020-08-04 | ３，３－二置換１９－ノルプレグナン化合物およびその使用 |
| JP2022101881A Active JP7617057B2 (ja) | 2011-10-14 | 2022-06-24 | ３，３－二置換１９－ノルプレグナン化合物およびその使用 |
| JP2025001804A Pending JP2025061026A (ja) | 2011-10-14 | 2025-01-06 | ３，３－二置換１９－ノルプレグナン化合物およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US20150291654A1 (enExample) |
| EP (3) | EP4717314A2 (enExample) |
| JP (5) | JP2014528485A (enExample) |
| CN (4) | CN119192266A (enExample) |
| AU (6) | AU2012323888A1 (enExample) |
| CA (2) | CA3152410A1 (enExample) |
| ES (1) | ES2738526T3 (enExample) |
| PL (1) | PL3572417T3 (enExample) |
| PT (1) | PT2766380T (enExample) |
| WO (1) | WO2013056181A1 (enExample) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016516786A (ja) * | 2013-04-17 | 2016-06-09 | セージ セラピューティクス， インコーポレイテッド | １９−ノル神経刺激性ステロイドおよびその使用方法 |
| JP2016531134A (ja) * | 2013-08-23 | 2016-10-06 | セージ セラピューティクス， インコーポレイテッド | 向神経活性ステロイド、組成物、及びその使用 |
| JP2021512909A (ja) * | 2018-02-11 | 2021-05-20 | 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 | ステロイド系誘導体モジュレーター、その製造方法及び応用 |
| JP2021513532A (ja) * | 2018-02-11 | 2021-05-27 | 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 | ステロイド系誘導体モジュレーター、その製造方法及び応用 |
| JP2022075974A (ja) * | 2016-07-11 | 2022-05-18 | セージ セラピューティクス， インコーポレイテッド | Ｃ１７、ｃ２０、およびｃ２１置換神経刺激性ステロイドおよびそれらの使用方法 |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2812250T3 (es) | 2005-11-28 | 2021-03-16 | Marinus Pharmaceuticals Inc | Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas |
| HUE062616T2 (hu) | 2011-09-08 | 2023-11-28 | Sage Therapeutics Inc | Neuroaktív szteroidok, készítmények és alkalmazásaik |
| EP4717314A2 (en) | 2011-10-14 | 2026-04-01 | Sage Therapeutics, LLC | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| SG10201606063RA (en) | 2012-01-23 | 2016-09-29 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| RS62761B1 (sr) | 2012-08-21 | 2022-01-31 | Sage Therapeutics Inc | Alopregnanolon za lečenje refraktornog epileptičkog statusa |
| US20150313915A1 (en) | 2012-11-30 | 2015-11-05 | The Regents Of The University Of California | Anticonvulsant activity of steroids |
| FI3932932T3 (fi) | 2013-03-13 | 2025-10-15 | Sage Therapeutics Inc | Neuroaktiivisia steroideja ja niiden käyttömenetelmiä |
| WO2014169836A1 (en) * | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| SMT202100509T1 (it) * | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| CA2918735C (en) | 2013-07-19 | 2023-08-01 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| SI3705488T1 (sl) * | 2014-05-29 | 2022-10-28 | Sage Therapeutics, Inc. | Nevroaktivni steroidi, sestavki in uporaba le-teh |
| JP6628745B2 (ja) | 2014-06-18 | 2020-01-15 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびその使用方法 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| CN107108689A (zh) * | 2014-09-17 | 2017-08-29 | 普瑞维卡斯有限公司 | C‑20类固醇化合物、其组合物和用于治疗包括震荡的创伤性脑损伤(tbi)的用途 |
| US20170233433A1 (en) * | 2014-10-16 | 2017-08-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| MY190408A (en) | 2014-10-16 | 2022-04-21 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| LT3250210T (lt) | 2015-01-26 | 2021-04-12 | Sage Therapeutics, Inc. | Kompozicijos ir būdai, skirti gydyti cns sutrikimus |
| DK3258939T3 (da) | 2015-02-20 | 2022-12-12 | Sage Therapeutics Inc | Neuroaktive steroider, sammensætninger og anvendelser heraf |
| EP3280420B1 (en) * | 2015-04-10 | 2024-03-27 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| AR105044A1 (es) | 2015-06-18 | 2017-08-30 | Sage Therapeutics Inc | Soluciones de esteroides neuroactivos y sus métodos de uso, recipiente |
| DK3812392T3 (da) | 2015-07-06 | 2025-07-21 | Sage Therapeutics Inc | Oxysteroler og fremgangsmåder til anvendelse deraf |
| PT3319611T (pt) | 2015-07-06 | 2021-04-22 | Sage Therapeutics Inc | Oxisteróis e métodos de utilização dos mesmos |
| WO2017007832A1 (en) * | 2015-07-06 | 2017-01-12 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| KR20180082457A (ko) | 2015-10-16 | 2018-07-18 | 마리누스 파마슈티컬스 인코포레이티드 | 나노입자들을 포함하는 주사용 뉴로스테로이드 제제들 |
| PH12018501923B1 (en) | 2016-03-08 | 2024-06-28 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
| ES2921010T3 (es) | 2016-04-01 | 2022-08-16 | Sage Therapeutics Inc | Oxisteroles y procedimientos de uso de los mismos |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2018009867A1 (en) | 2016-07-07 | 2018-01-11 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| CA3030420C (en) | 2016-07-11 | 2025-11-18 | Sage Therapeutics, Inc. | C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE |
| KR20230050474A (ko) | 2016-08-11 | 2023-04-14 | 오비드 테라퓨틱스 인크. | 간질 장애의 치료를 위한 방법 및 조성물 |
| TW202604538A (zh) | 2016-08-23 | 2026-02-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| MA46351A (fr) | 2016-09-30 | 2021-06-02 | Sage Therapeutics Inc | Oxystérols substitués en c7 et procédés en tant que modulateurs nmda |
| DK3529257T3 (da) | 2016-10-18 | 2023-08-07 | Sage Therapeutics Inc | Oxysteroler og fremgangsmåder til anvendelse deraf |
| KR102521573B1 (ko) * | 2016-10-18 | 2023-04-14 | 세이지 테라퓨틱스, 인크. | 옥시스테롤 및 그의 사용 방법 |
| US20210228596A1 (en) * | 2017-10-12 | 2021-07-29 | Sage Therapeutics, Inc. | Method of treating cns disorders with neurosteroids and gabaergic compounds |
| US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| CA3086299A1 (en) | 2017-12-22 | 2019-06-27 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| IL312610B2 (en) | 2018-12-05 | 2026-05-01 | Sage Therapeutics Llc | Neuroactive steroids and methods of using them |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| TWI848034B (zh) | 2018-12-21 | 2024-07-11 | 美商賽吉醫療公司 | 神經活性類固醇及其組合物 |
| JP7670626B2 (ja) | 2019-05-31 | 2025-04-30 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド及びその組成物 |
| EP4009982A4 (en) | 2019-08-05 | 2023-08-09 | Marinus Pharmaceuticals, Inc. | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS |
| WO2021023213A1 (zh) * | 2019-08-07 | 2021-02-11 | 上海翰森生物医药科技有限公司 | 一种甾族类衍生物调节剂的盐及其晶型 |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| US20210188897A1 (en) * | 2019-12-05 | 2021-06-24 | Sparx Therapeutics, Inc. | Neuroactive steroids and compositions and methods thereof |
| AU2020395254B2 (en) | 2019-12-06 | 2026-04-02 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating tuberous sclerosis complex |
| WO2021174205A1 (en) * | 2020-02-27 | 2021-09-02 | Brii Biosciences, Inc. | Prodrugs of neuroactive steroids |
| AU2021238346A1 (en) | 2020-03-18 | 2022-09-29 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| CN115551514A (zh) | 2020-03-25 | 2022-12-30 | 萨奇治疗股份有限公司 | 用于治疗呼吸系统病症的药物的用途 |
| IL309922A (en) | 2021-07-28 | 2024-03-01 | Sage Therapeutics Inc | Crystalline forms of a neuroactive steroid |
| US20250368678A1 (en) * | 2022-06-09 | 2025-12-04 | Shandong Luye Pharmaceutical Co., Ltd. | 19-nor-c3,3-disubstituted c21-azacyclo-substituted steroid and method for using same |
| WO2024059608A1 (en) | 2022-09-15 | 2024-03-21 | Sage Therapeutics, Inc. | Deuterated neuroactive steroids |
| CN120936616A (zh) | 2023-03-14 | 2025-11-11 | 库里亚西班牙公司 | 用于制备3α-羟基-3β-烷基类固醇的方法和中间体 |
| CN122341622A (zh) * | 2023-12-08 | 2026-07-03 | 山东绿叶制药有限公司 | 一种gabaa受体调节剂的晶型及其制备方法和应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994027608A1 (en) * | 1993-05-24 | 1994-12-08 | Cocensys, Inc. | Methods and compositions for inducing sleep |
| WO1995021617A1 (en) * | 1994-02-14 | 1995-08-17 | Cocensys, Inc. | Androstanes and pregnanes for allosteric modulation of gaba receptor |
| WO1996016076A1 (en) * | 1994-11-23 | 1996-05-30 | Cocensys, Inc. | Androstane and pregnane series for allosteric modulation of gaba receptor |
| WO1998005337A1 (en) * | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1994E (fr) | 1902-11-20 | 1903-11-24 | Jules Bernard | Dispositif de suspension élastique amortisseur de chocs pour chassis, caisses de véhicules, sièges et sommiers élastiques |
| US2856415A (en) | 1957-11-13 | 1958-10-14 | Searle & Co | 3,19-dihydroxy-5-androstene derivatives |
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| US3169134A (en) | 1963-03-21 | 1965-02-09 | Searle & Co | 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols |
| BE754111A (fr) | 1969-07-29 | 1971-01-29 | Upjohn Co | Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation |
| US3943124A (en) | 1970-12-17 | 1976-03-09 | Gordon Hanley Phillipps | Chemical compounds |
| GB1380246A (en) | 1970-12-17 | 1975-01-08 | Glaxo Lab Ltd | 3alpha-hydroxy-androstanes and esters thereof |
| US3983111A (en) | 1972-05-05 | 1976-09-28 | Glaxo Laboratories Limited | Steroidal anaesthetics of the pregnane and 19-norpregnane series |
| GB1430942A (en) | 1972-05-05 | 1976-04-07 | Glaxo Lab Ltd | 21-substituted 3alpha-hydroxy pregnanes |
| GB1436324A (en) | 1972-05-12 | 1976-05-19 | Glaxo Lab Ltd | Anaesthetic 3alpha-hydroxy pregnanes |
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| DE2526373C2 (de) | 1975-06-11 | 1983-11-10 | Schering AG, 1000 Berlin und 4709 Bergkamen | Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden |
| US4192871A (en) * | 1976-01-06 | 1980-03-11 | Glaxo Laboratories Limited | Chemical compounds |
| GB1570394A (en) | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
| GB1581234A (en) | 1976-04-05 | 1980-12-10 | Glaxo Operations Ltd | 11a - amino - 3a - hydroxysteroids |
| DE2632677A1 (de) | 1976-07-16 | 1978-01-26 | Schering Ag | Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung |
| US4389345A (en) | 1981-10-09 | 1983-06-21 | G.D. Searle & Co. | 3-Oxoestra-17-acetonitrile and unsaturated analogs |
| US4495102A (en) | 1982-09-03 | 1985-01-22 | G. D. Searle & Co. | Aminoalkyl steroids |
| EP0382790A4 (en) * | 1987-08-25 | 1991-03-27 | Kelvin W. Gee | Compositions and methods for alleviating stress, anxiety and seizure activity |
| US5319115A (en) | 1987-08-25 | 1994-06-07 | Cocensys Inc. | Method for making 3α-hydroxy, 3β-substituted-pregnanes |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| CA2118938A1 (en) | 1991-09-13 | 1993-04-01 | Kelvin W. Gee | Novel gabaa receptor with steroid binding sites |
| DE4232681C2 (de) | 1992-09-29 | 1994-11-24 | Sigma Tau Ind Farmaceuti | 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung |
| EP0656365B1 (en) | 1993-12-02 | 1997-04-09 | Akzo Nobel N.V. | Substituted 2beta-morpholinoandrostane derivatives |
| CZ300694A3 (en) | 1993-12-02 | 1996-05-15 | Akzo Nobel Nv | Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof |
| US5939545A (en) * | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| JP2002500616A (ja) | 1994-07-21 | 2002-01-08 | ファルマシア・アンド・アップジョン・カンパニー | 神経学的に活性なアミノステロイド |
| PT837874E (pt) | 1995-06-06 | 2005-03-31 | Euro Celtique Sa | Esteroides neuroactivos da serie androstano e pregnano |
| US5994334A (en) | 1997-02-05 | 1999-11-30 | University Of Maryland | Androgen synthesis inhibitors |
| US5935545A (en) | 1997-07-11 | 1999-08-10 | E. I. Du Pont De Nemours And Company | Process for producing an aqueous solution comprising ferric chloride |
| UA73736C2 (en) * | 1999-04-29 | 2005-09-15 | Euro Celtic S A | Method for alleviating or preventing insomnia and inducing anesthesia |
| US7018406B2 (en) | 1999-11-17 | 2006-03-28 | Corevalve Sa | Prosthetic valve for transluminal delivery |
| WO2001060836A1 (en) | 2000-02-18 | 2001-08-23 | Taiho Pharmaceutical Co., Ltd. | Process for the preparation of steroid derivatives |
| US6855836B2 (en) | 2000-10-26 | 2005-02-15 | Jenapharm Gmbh & Co. Kg | 17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds |
| CA2427817C (en) | 2000-11-03 | 2009-04-14 | Washington University | Estrone-derivatives having cytoprotective activity |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| DE602004024966D1 (de) | 2003-03-24 | 2010-02-25 | Sterix Ltd | Oestrogenderivate als steroid sulphatase inhibitoren |
| CA2527019A1 (en) | 2003-05-29 | 2005-01-06 | Washington University | Neuroactive 13,24-cyclo-18,21-dinorcholanes and structurally-related pentacyclic steroids |
| JP2007512344A (ja) | 2003-11-24 | 2007-05-17 | メルク エンド カムパニー インコーポレーテッド | エストロゲン受容体調節剤 |
| WO2005105822A2 (en) | 2004-04-23 | 2005-11-10 | Euro-Celtique S.A. | 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
| WO2006037016A2 (en) | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| AU2005330504B2 (en) | 2004-09-29 | 2010-10-28 | Harbor Biosciences, Inc. | Steroid analogs and characterization and treatment methods |
| DK2168585T3 (da) | 2005-06-09 | 2012-02-27 | Euro Celtique Sa | Farmaceutiske sammensætninger af en neuroaktiv steroid og anvendelser deraf |
| US20090203658A1 (en) | 2007-01-08 | 2009-08-13 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| DE102007027636A1 (de) | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| CA2698172C (en) | 2007-06-15 | 2014-02-18 | Cook, Kevin M. | Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties |
| GB0711948D0 (en) | 2007-06-20 | 2007-08-01 | Bionature E A Ltd | Neurosteriod compounds |
| CN101412742B (zh) | 2007-10-19 | 2013-07-31 | 天津金耀集团有限公司 | 一种抑制血管新生的硝酸酯药物 |
| US20090264443A1 (en) | 2008-04-18 | 2009-10-22 | David Helton | Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds |
| CN101624414B (zh) | 2008-07-07 | 2013-02-13 | 天津金耀集团有限公司 | 一种抑制血管新生的硝酸酯药物 |
| CZ2008434A3 (cs) | 2008-07-10 | 2009-12-09 | Ústav organické chemie a biochemie Akademie ved CR, v. v. i. | Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití |
| US20110152840A1 (en) | 2009-12-23 | 2011-06-23 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| AU2011284606A1 (en) | 2010-07-30 | 2013-03-14 | Pharmacellion Ltd | Compounds and methods for treating neoplasia |
| US20120214987A1 (en) | 2010-12-15 | 2012-08-23 | Yu Ge | Methods and compounds for preparing 3alpha-oxygen substituted steroids |
| CZ201181A3 (cs) | 2011-02-15 | 2012-09-12 | Ústav organické chemie a biochemie Akademie ved CR, v.v.i. | Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující |
| US9457033B2 (en) | 2011-02-15 | 2016-10-04 | Socpra Sciences Et Genie, S.E.C. | Steroid alkaloids and uses thereof as antimicrobial agents against electron transport-deficient microbes and as potentiators for antimicrobial agents against pathogenic bacteria |
| US9388210B2 (en) | 2011-02-25 | 2016-07-12 | Washington University | Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| ES2762098T3 (es) | 2011-03-23 | 2020-05-22 | Etsuro Ito | Método y kit para medición de superalta sensibilidad de proteína y ácido nucleico, y nuevo sustrato enzimático |
| WO2013019711A2 (en) | 2011-07-29 | 2013-02-07 | The Regents Of The University Of California | NOVEL 17β-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS |
| HUE062616T2 (hu) | 2011-09-08 | 2023-11-28 | Sage Therapeutics Inc | Neuroaktív szteroidok, készítmények és alkalmazásaik |
| EP4717314A2 (en) | 2011-10-14 | 2026-04-01 | Sage Therapeutics, LLC | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| US20150175651A1 (en) | 2012-06-15 | 2015-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2014028398A2 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| US9765110B2 (en) | 2012-10-08 | 2017-09-19 | Washington University | Neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| WO2014071449A1 (en) | 2012-11-09 | 2014-05-15 | Goodchild Investments Pty Ltd | Neuroactive steroids and their use to facilitate neuroprotection |
| DK2935307T3 (en) | 2012-12-18 | 2018-07-30 | Univ Washington | NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS USED IN METHODS OF TREATMENT |
| US8939545B2 (en) | 2012-12-20 | 2015-01-27 | Eastman Kodak Company | Inkjet printing with managed airflow for condensation control |
| US9562026B2 (en) | 2013-03-14 | 2017-02-07 | Washington University | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors |
| CN117304245A (zh) | 2013-04-17 | 2023-12-29 | 萨奇治疗股份有限公司 | 刺激神经活性的19-去甲类固醇及其使用方法 |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| SMT202100509T1 (it) | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| CA2918735C (en) | 2013-07-19 | 2023-08-01 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| CN105579043B (zh) | 2013-08-23 | 2021-09-14 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物和其用途 |
| SI3705488T1 (sl) | 2014-05-29 | 2022-10-28 | Sage Therapeutics, Inc. | Nevroaktivni steroidi, sestavki in uporaba le-teh |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| MY190408A (en) | 2014-10-16 | 2022-04-21 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| US20170233433A1 (en) | 2014-10-16 | 2017-08-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| LT3250210T (lt) | 2015-01-26 | 2021-04-12 | Sage Therapeutics, Inc. | Kompozicijos ir būdai, skirti gydyti cns sutrikimus |
| DK3258939T3 (da) | 2015-02-20 | 2022-12-12 | Sage Therapeutics Inc | Neuroaktive steroider, sammensætninger og anvendelser heraf |
| UY36741A (es) | 2015-06-21 | 2016-12-30 | Prevacus Inc | Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales |
| US20180250313A1 (en) | 2015-09-08 | 2018-09-06 | Viewpoint Therapeutics, Inc. | Compounds and formulations for treating ophthalmic diseases |
| KR20180082457A (ko) | 2015-10-16 | 2018-07-18 | 마리누스 파마슈티컬스 인코포레이티드 | 나노입자들을 포함하는 주사용 뉴로스테로이드 제제들 |
| MA43284A (fr) | 2015-11-20 | 2018-09-26 | Sage Therapeutics Inc | Composés et leurs méthodes d'utilisation |
| PH12018501923B1 (en) | 2016-03-08 | 2024-06-28 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
| US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
| CA3030420C (en) | 2016-07-11 | 2025-11-18 | Sage Therapeutics, Inc. | C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE |
| WO2018013613A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| TW202604538A (zh) | 2016-08-23 | 2026-02-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| US11285139B2 (en) | 2017-08-31 | 2022-03-29 | Takeda Pharmaceutical Company Limited | Treatment of CNS conditions |
-
2012
- 2012-10-12 EP EP25222656.8A patent/EP4717314A2/en active Pending
- 2012-10-12 AU AU2012323888A patent/AU2012323888A1/en not_active Abandoned
- 2012-10-12 CN CN202411226456.XA patent/CN119192266A/zh active Pending
- 2012-10-12 CN CN201280060883.4A patent/CN104136452A/zh active Pending
- 2012-10-12 CA CA3152410A patent/CA3152410A1/en active Pending
- 2012-10-12 PL PL19169283.9T patent/PL3572417T3/pl unknown
- 2012-10-12 US US14/351,449 patent/US20150291654A1/en not_active Abandoned
- 2012-10-12 PT PT12781534T patent/PT2766380T/pt unknown
- 2012-10-12 ES ES12781534T patent/ES2738526T3/es active Active
- 2012-10-12 CA CA2852057A patent/CA2852057C/en active Active
- 2012-10-12 CN CN201810869360.3A patent/CN108976272B/zh active Active
- 2012-10-12 WO PCT/US2012/060136 patent/WO2013056181A1/en not_active Ceased
- 2012-10-12 EP EP12781534.8A patent/EP2766380B1/en active Active
- 2012-10-12 EP EP19169283.9A patent/EP3572417B1/en active Active
- 2012-10-12 CN CN202110494113.1A patent/CN113234114A/zh active Pending
- 2012-10-12 JP JP2014535962A patent/JP2014528485A/ja not_active Withdrawn
-
2017
- 2017-07-26 AU AU2017208284A patent/AU2017208284B2/en active Active
- 2017-08-21 US US15/681,983 patent/US10435431B2/en active Active
- 2017-12-07 JP JP2017235371A patent/JP6745783B2/ja active Active
-
2019
- 2019-04-30 AU AU2019203046A patent/AU2019203046B2/en active Active
- 2019-08-22 US US16/548,248 patent/US20200223884A1/en not_active Abandoned
-
2020
- 2020-08-04 JP JP2020132282A patent/JP7096864B2/ja active Active
- 2020-10-22 US US17/077,025 patent/US20210040141A1/en not_active Abandoned
-
2021
- 2021-07-08 AU AU2021204782A patent/AU2021204782B2/en active Active
-
2022
- 2022-06-24 JP JP2022101881A patent/JP7617057B2/ja active Active
- 2022-10-19 US US17/969,105 patent/US20230287037A1/en not_active Abandoned
-
2023
- 2023-06-26 AU AU2023204015A patent/AU2023204015B2/en active Active
-
2025
- 2025-01-06 JP JP2025001804A patent/JP2025061026A/ja active Pending
- 2025-12-09 AU AU2025279604A patent/AU2025279604A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994027608A1 (en) * | 1993-05-24 | 1994-12-08 | Cocensys, Inc. | Methods and compositions for inducing sleep |
| WO1995021617A1 (en) * | 1994-02-14 | 1995-08-17 | Cocensys, Inc. | Androstanes and pregnanes for allosteric modulation of gaba receptor |
| WO1996016076A1 (en) * | 1994-11-23 | 1996-05-30 | Cocensys, Inc. | Androstane and pregnane series for allosteric modulation of gaba receptor |
| WO1998005337A1 (en) * | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
Non-Patent Citations (2)
| Title |
|---|
| PHLLIPPS G.H., J. STEROID BIOCHEM., vol. 6, JPN6016035488, 1975, pages 607 - 13, ISSN: 0003399901 * |
| UPASANI R.B. ET AL., J. MED. CHEM., vol. 40, no. 1, JPN6016035486, 1997, pages 73 - 84, ISSN: 0003399900 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016516786A (ja) * | 2013-04-17 | 2016-06-09 | セージ セラピューティクス， インコーポレイテッド | １９−ノル神経刺激性ステロイドおよびその使用方法 |
| JP2016531134A (ja) * | 2013-08-23 | 2016-10-06 | セージ セラピューティクス， インコーポレイテッド | 向神経活性ステロイド、組成物、及びその使用 |
| JP2022075974A (ja) * | 2016-07-11 | 2022-05-18 | セージ セラピューティクス， インコーポレイテッド | Ｃ１７、ｃ２０、およびｃ２１置換神経刺激性ステロイドおよびそれらの使用方法 |
| JP2021512909A (ja) * | 2018-02-11 | 2021-05-20 | 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 | ステロイド系誘導体モジュレーター、その製造方法及び応用 |
| JP2021513532A (ja) * | 2018-02-11 | 2021-05-27 | 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 | ステロイド系誘導体モジュレーター、その製造方法及び応用 |
| JP7438956B2 (ja) | 2018-02-11 | 2024-02-27 | 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 | ステロイド系誘導体モジュレーター、その製造方法及び応用 |
| JP2024045458A (ja) * | 2018-02-11 | 2024-04-02 | 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 | ステロイド系誘導体モジュレーター、その製造方法及び応用 |
| JP2024163113A (ja) * | 2018-02-11 | 2024-11-21 | 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 | ステロイド系誘導体モジュレーター、その製造方法及び応用 |
| JP7741907B2 (ja) | 2018-02-11 | 2025-09-18 | 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 | ステロイド系誘導体モジュレーター、その製造方法及び応用 |
| JP7848273B2 (ja) | 2018-02-11 | 2026-04-20 | 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 | ステロイド系誘導体モジュレーター、その製造方法及び応用 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7617057B2 (ja) | ３，３－二置換１９－ノルプレグナン化合物およびその使用 | |
| AU2025203873A1 (en) | Neuroactive steroids, compositions, and uses thereof | |
| JP2016514967A (ja) | 神経刺激性ステロイド、組成物およびそれらの使用 | |
| HK40018206A (en) | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof | |
| HK40001824A (en) | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof | |
| HK40001824B (en) | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof | |
| HK40120913A (en) | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof | |
| HK1201274B (en) | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141031 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20141031 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150925 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150925 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160913 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161207 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170208 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170313 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170807 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171207 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20171215 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20180129 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20180309 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20190116 |